title: [Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease].
abstract: Iron supplementation is essential for the treatment of anemia in the chronic kidney disease (CKD) population. Liposomial iron is a preparation of ferric pyrophosphate carried within a phospholipidic membrane. Compared to other oral formulations, it is well absorbed from the gut and demonstrates high bioavailability together with a lower incidence of side effects. The aim of our study was to evaluate the effectiveness of treatment with liposomial iron compared to intravenous iron in a CKD population with anemia and iron deficiency. Our study is a single-center, prospective, randomized, fourth-phase study. Enrollment for the study began in October 2011 and CKD 3, 4 and 5 patients were randomized to receive either intravenous iron or liposomial iron in a 1:2 ratio. The primary outcome was set as the increase of hemoglobin from baseline. The secondary outcomes were the reduction of erythropoietin dosage by at least 25% in patients treated with erythropoiesis-stimulating agents and an increase in serum ferritin of 100 ng/ml from baseline values. In the preliminary study, 21 patients were analyzed, 14 of whom were treated with oral liposomial iron and 7 with intravenous iron. The observed increase of hemoglobin at 8 weeks compared to baseline was similar in both groups but was significant in the liposomial group only.
authors.forename: Bianca
authors.initials: B
authors.lastname: Visciano
authors.forename: Paola
authors.initials: P
authors.lastname: Nazzaro
authors.forename: Germano
authors.initials: G
authors.lastname: Tarantino
authors.forename: Alessandro
authors.initials: A
authors.lastname: Taddei
authors.forename: Antonio
authors.initials: A
authors.lastname: Del Rio
authors.forename: Giusi Rosaria
authors.initials: GR
authors.lastname: Mozzillo
authors.forename: Eleonora
authors.initials: E
authors.lastname: Riccio
authors.forename: Ivana
authors.initials: I
authors.lastname: Capuano
authors.forename: Antonio
authors.initials: A
authors.lastname: Pisani
mesh_terms: D061605:Administration, Intravenous; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology; D011756:Diphosphates / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007501:Iron / Q000008:administration & dosage*; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D051436:Renal Insufficiency, Chronic / Q000150:complications
chemical_list: D011756:Diphosphates; D008081:Liposomes; D007501:Iron; C049051:ferric pyrophosphate